GlobeNewswire

Percona Offers New Services and Software Products to Help Organizations Achieve Performant, Durable Database Environments

Dela

Percona's Expertise in Platform as a Service, Database as a Service and More Enables Administrators to Ensure Optimal Performance While Shifting Focus to More Strategic Tasks

RALEIGH, N.C., April 26, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB®, MongoDB®, PostgreSQL, and other open source database solutions and services, announced new services and software products, including a new Percona DBA service, new support tiers, and the general availability of Percona Server for MongoDB 3.6, the latest version of Percona's free, enhanced, drop-in replacement for the MongoDB Community Edition.

As open source databases are now standard in the enterprise, mission-critical data workloads, whether on-premises or in the cloud, require expert DBAs for architectural decisions, performance tuning, security compliance, and query optimization, as well as monitoring and alert response. Percona has helped thousands of customers achieve better performance, better cost savings and better ROI by ensuring optimal performance while letting DBAs shift their focus to improving applications and better supporting their business.

Organizations are increasingly looking to deploy these open source databases in public cloud environments to benefit from the flexibility, scalability and economics of cloud deployments. Today's announcements reflect Percona's commitment to making it easier for organizations to take advantage of the cloud by providing comprehensive support for migrating open source databases to the cloud and providing support and DBA services specifically designed for the evolving role of database administrators.

Percona DBA Service
Percona DBA Service is a flexible managed database service that offers a guaranteed set of scheduled, proactive deliverables. With the collective experience of a global team of experts to manage high performance relational database environments in on-premises and cloud environments, Percona DBA Service provides performance tuning, growth planning, security assessments, health monitoring and reporting, 24x7x365 responsive services, business continuity reviews and more.

Cloud services like Amazon Aurora, Amazon RDS, Google Cloud and Microsoft Azure are easy to set up, operate and scale, and provide cost-efficient and resizable capacity while automating time-consuming administrative tasks. However, mission-critical databases deployed in DBaaS environments still require important architectural decisions, performance tuning, security compliance and query optimization, as well as monitoring and alert response. Percona DBA Service for Amazon Aurora, Amazon RDSGoogle Cloud and Microsoft Azure offer peace of mind that the database architecture is being proactively managed and improved.

New Support Tiers
Percona's new Essential, Standard and Premium Support tiers provide unbiased, comprehensive, responsive and cost-effective database subscriptions for MySQL, MariaDB, MongoDB and PostgreSQL open source databases. Available 24x7x365, Percona Support helps organizations navigate complexity and mitigate risks using best-of-breed open source software, avoiding vendor lock-in.

In addition, Percona is launching new DBaaS-focused support tiers that align with the changing role of database administrators who manage cloud environments. These administrators require less support for the routine management of operational tasks that are automated in the cloud, allowing Percona to reduce costs while still providing unbiased consultative support services to help customers properly configure their instances, improve schemas, tune queries, diagnose problems, benefit from additional database features, and ultimately get more out of their deployments.

The new support tiers will be available starting July 1, 2018.

Percona Server for MongoDB 3.6.
Percona has announced the general availability of Percona Server for MongoDB 3.6, the latest version of the company's free, enhanced, drop-in replacement for MongoDB Community Edition. Percona Server for MongoDB 3.6 contains all the new features introduced in MongoDB Community Edition 3.6, including:

  • Retryable writes, which ensures data is written to the database even after a network error occurs
  • Causal consistency, which allows reliable reads from secondary nodes
  • Security enhancements, including improved network listening and more restrictive access controls
  • Aggregation and array improvements, for greater querying flexibility

With more than 300,000 downloads, Percona Server for MongoDB provides all the cost and agility benefits of free, proven open source software, along with practical enterprise features. The greater security, reliability and flexibility of Percona Server for MongoDB 3.6 makes it ideal for running the document-based NoSQL MongoDB database in production environments to support product catalogs, online shopping carts, Internet of Things (IoT) applications, mobile/social apps and more.

Quotes

Peter Zaitsev,  Co-founder and CEO of Percona
"Mission-critical database workloads require expertise to ensure resources are being used to their best advantage to obtain the highest possible application performance. Percona is expanding and evolving our offerings to ensure organizations have a hands-on partner, with enterprise-ready products, tools and services, to ensure a consistently performing and durable database environment."

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com 

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for MySQL® , MariaDB®, MongoDB® ,and PostgreSQL across traditional and cloud-based platforms. The company provides SoftwareSupportConsulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum